Voclosporin (ISATX247; LX211; LX 214; Luveniq; Lupkynis) is a novel and potent calcineurin inhibitor approved in January 2021 by the US FDA for use as an immunosuppressant medication to treat lupus nephritis. Voclosporin is an immunosuppressant that binds and inhibits calcineurin, a type of protein found in the body. It can reduce the activation of T cells and stabilizes podocytes, thereby reducing proteinuria.

纯度：≥98%

CAS：515814-01-4